Associations between Cognitive Impairment (CI) and other geriatric vulnerabilities of older patients at the time of cancer treatment initiation, and two-year survival^*: Multivariate Cox regressions stratified for diagnosis and disease status^**.

<p>Associations between Cognitive Impairment (CI) and other geriatric vulnerabilities of older patients at the time of cancer treatment initiation, and two-year survival^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0159734#t004fn001" target="_blank">*</a>}: Multivariate Cox regressions stratified for diagnosis and disease status^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0159734#t004fn002" target="_blank">**</a>}.</p

CD10 immunostaining of the myoepithelial cell (MECs) layer (original magnification <b>×</b>200).

<p>(A) intense staining (3) and a circumferential membrane expression (3) observed on normal breast (score = 6); (B) intense staining (3) and a circumferential membrane expression (3) observed on DCIS (score = 6); (C) intermediate staining (2) and partial membrane expression (2) observed on DCIS (score = 4); (D) weak staining (1) and focal membrane expression (1) observed on DCIS (score = 2).</p

Combined CD10 and VPNI risk.

<p>(A) Cross-tabulation between CD10 qRT-PCR expression and VNPI score. (B) Disease-free survival analysis for patients with DCIS according to CD10 mRNA expression by qRT-PCR combined with VNPI risk group.</p

Kaplan-Meir overall survival estimates of two-year overall survival between older patients without a cognitive impairment (MoCA ≥26; n = 4) and patients with a cognitive impairment (MoCA <26; n = 20) when treatment for breast, prostate, or colorectal cancer is initiated.

<p>Kaplan-Meir overall survival estimates of two-year overall survival between older patients without a cognitive impairment (MoCA ≥26; n = 4) and patients with a cognitive impairment (MoCA <26; n = 20) when treatment for breast, prostate, or colorectal cancer is initiated.</p

Sociodemographic and disease-related characteristics of older patients at the time of cancer treatment initiation, stratified for Survivors/Non-Survivors at 2 years (n = 357).

<p>Sociodemographic and disease-related characteristics of older patients at the time of cancer treatment initiation, stratified for Survivors/Non-Survivors at 2 years (n = 357).</p

Associations between sociodemographic characteristics, disease-related characteristics, Cognitive Impairment (CI) and other geriatric vulnerabilities of older patients at the time of cancer treatment initiation, and two-year survival: Univariate Cox regressions.

<p>Associations between sociodemographic characteristics, disease-related characteristics, Cognitive Impairment (CI) and other geriatric vulnerabilities of older patients at the time of cancer treatment initiation, and two-year survival: Univariate Cox regressions.</p

CD10 expression and clinical outcome.

<p>(A) scatter plot of CD10 expression evaluated by qRT-PCR for normal (N = 11) and DCIS (N = 154) samples. All normal samples and one-third of the DCIS were considered CD10 positive. (B) Kaplan-Meier curves of disease-free survival for patients with DCIS (N = 154) according to CD10 mRNA expression by qRT-PCR expression. (C) Kaplan-Meier curves of disease-free survival for patients with DCIS treated by tumorectomy only or tumorectomy and radiation (N = 77) according to CD10 mRNA expression by qRT-PCR expression.</p

Efficacy results.

<p>Efficacy results.</p

CONSORT Diagram.

<p>CONSORT Diagram.</p

Adverse events of grade 3 or 4.

<p>Adverse events of grade 3 or 4.</p